A Phase I Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma

Trial Profile

A Phase I Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2015

At a glance

  • Drugs Aldesleukin (Primary) ; Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Based on results of this trial, a phase II trial will be conducted using intratumoural ipilimumab and aldesleukin in conjunction with systemic immunotherapy, according to the abstract presented at ASCO 2015.
    • 02 Jun 2015 Results at ipilimumab dose levels of 0.5, 1 and 2mg presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top